Syracuse

Exposure-response relationship of cabozantinib in patients with metastatic renal cell carcinoma treated in routine care

Archive ouverte

Blanchet, Benoit | Xu-Vuilard, Alexandre | Jouinot, Anne | Puisset, Florent | Combarel, David | Huillard, Olivier | Le Louedec, Félicien | Thomas, Fabienne | Teixeira, Marcus | Flippot, Ronan | Mourey, Loic | Albiges, Laurence | Pudlarz, Thomas | Joly, Charlotte | Tournigand, Christophe | Chauvin, Jonathan | Puszkiel, Alicja | Chatelut, Etienne | Decleves, Xavier | Vidal, Michel | Goldwasser, François | Oudard, Stéphane | Medioni, Jacques | Vano, Yann-Alexandre

Edité par CCSD ; Cancer Research UK -

International audience. Interindividual pharmacokinetic variability may influence the clinical benefit or toxicity of cabozantinib in metastatic renal cell carcinoma (mRCC). We aimed to investigate the exposure-toxicity and exposure-response relationship of cabozantinib in unselected mRCC patients treated in routine care.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion